CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
We have now added a new section called the "Assay History List" to the "At A Gla...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...